Small study shows curative benefit of allogeneic hematopoietic cell transplantation mantle cell lymphoma
from Cancer Therapy Advisor
In a retrospective study of 36 patients, researchers found that allogeneic hematopoietic cell transplantation (allo-HCT) could be a curative treatment in patients with mantle cell lymphoma (MCL). After 5 years, more than half (54 percent) of patients who underwent allo-HCT for MCL were still alive. Median overall survival (OS) was determined to be 86 months. In addition, progression-free survival (PFS) numbers were promising; the median PFS was 54 months, and after 5 years of observation, PFS was 49 percent.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063